The changes of clinical practice guidelines for colorectal cancer in the 2008-2012 National Comprehensive Cancer Network

doi:10.3877/cma.j.issn.2095-3224.2012.01.02

Abstract

Abstract:

It is significant that National Comprehensive Cancer Network(NCCN) Guidelines for specification of colorectal cancer diagnosis and treatment.The contents is updated every year, which means the hot, difficulty or doubt spots of the field of cancer research.This paper reviews the focus of the 2008-2012 Guide updates, looking back at the stories of colorectal cancer diagnosis and treatment progress, hoping to find a little inspiration.

Key words: Colorectal neoplasms, National Comprehensive Cancer Network

Xi-shan WANG. The changes of clinical practice guidelines for colorectal cancer in the 2008-2012 National Comprehensive Cancer Network[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2012, 01(01): 6-11.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2012.01.02

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2012/V01/I01/6

References 14

[1]	Lopez-Kostner F,Lavery IC,Hool GR, et al.Total mesorectal excision is not necessary for cancers of the upper rectum[J]. Surgery, 1998, 124(4): 612-617.
[2]	Clinical Outcomes of Surgical Therapy Study Croup.A comparison of laparoscopically assisted and open colectomy forcolon cancer[J]. N Engl J Med, 2004, 350(20): 2050-2059.
[3]	Carden OJ,Rees M,Poston CJ, et al.Guidelines for resectionof colorectal cancer liver metastases[J]. Cut, 2006, 55 Suppl3: Sl-8.
[4]	Charnsangavej C,Clary B,Fong M, et al.Selection of patients for resection of hepatic colorectal metastases：expert consensus statement[J]. Ann Surg Oncol, 2006, 13(10): 1261-1268.
[5]	Roh MS,Colangelo LH,O'Connell MJ, et al.Preoperative multimodality therapy improves disease-free survival in patients wich carcinoma of the rectum：NSABP R-03[J]. J Clin Oncol, 2009, 27(31): 5124-5130.
[6]	Gunderson LL,Jessup JM,Sargent DJ, et al.Revised TN categorization for colon cancer based on national survival outcomes data[J]. J Clin Oncol, 2010, 28(2): 264-271.
[7]	Sargent DJ,Marsoni S,Thibodeau SN, et al.Defectivemismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer[J]. J Clin Oncol, 2010, 28(20): 3219-3226.
[8]	Nordlinger B,Sorbye H,Collette L, et al.Final results of the EORTC Intergroup randomized phaseⅢ study 40983[EPOC]evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases[J]. J Clin Oncol, 2007, 25(18)suppl: LBA5.
[9]	Ychou M,Hohenberger W,Thezenas S, et al.A randomizedphaseⅢ study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resectionof liver metastases from colorectal cancer[J]. Ann Oncol, 2009, 20(12): 1964-1970.
[10]	Chung KY,Shia J,Keme ny NE, et al.Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growch factor receptor byimmunohistochemistry[J]. J Clin Oncol, 2005, 23(9): 1803-1810.
[11]	Lièvre A,Bachet JB,Boige V, et al.KRAS mutations as an independent prognostic factor in patients with advanced colorectaI cancer treated with cetuximab[J]. J Clin Oncol, 2008, 26(3): 374-379.
[12]	Karapetis CS,Khambata-F ord S,Jonker DJ, et al.K-rasmutations and benefit from cetuximab in advanced colorectal cancer[J]. N Engl J Med, 2008, 359(17): 1757-1765.
[13]	Di Nicolantonio F,Martini M,Molinari F, et al.Wild-type BRAF is required for response to panituniumab or cetuximab in metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(35): 5705-5712.
[14]	Maughan TS,Adams R,Smith CG, et al.Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy(CT)in first-lineadvanced colorectal cancer(aCRC)：Mature results of theMRC COIN trial[J]. J Clin Oncol, 2010, 28(15): 3502.

[1]	Qingshan Luo, Haitao Mei, Jialing Hao, Jinfeng Cai, Runkai Zhou, Yugang Wen. Connexin 43 inhibiting the proliferation of colorectal cancer by regulating the cell cycle [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(05): 344-349.
[2]	Jinye Chen, Qianlong Ling, Bing Zhu, Jie Luo. Expression and clinical significance of complement B factor in colorectal cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(03): 192-198.
[3]	Yaocheng Sun, Jianjun Tang, Weiyuan Zhang, Chuanlei Liu. Study on the prognostic value of positive lymph node ratio and log odds of positive lymph nodes in colorectal cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(03): 204-208.
[4]	Lichun Xie, Qingfen Ou, Qiuping Zhang, Sheng Ye. Clinical application of simplified and standard liver MRI protocols in follow-up of patients with liver metastases from colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(04): 434-437.
[5]	Yexin Shi, Xiang Ma, Ming Lu, Qingcheng Xia, Pengchao Wang, Qingyu Song, Qinghong Zhao. Research progress of colorectal tumor localization under laparoscopy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(04): 463-466.
[6]	Pengcheng Ji, Yimin E, Chen Lu, Chunzhao Yu. Research progress of circulating exosome-related biomarkers in the diagnosis of colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(04): 265-273.
[7]	Jiaying Li, Xudan Wang, Xue Liang, lei Zhang, Jiaying Li. Analysis of mortality trends of colorectal cancer in China from 1990 to 2021 [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(04): 274-279.
[8]	Wei Ge, Gang Chen. Clinical research on the value of carbon nanoparticles navigation lymphatic tracing in TNM staging of colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(04): 288-293.
[9]	Jing Cui, Yifan Bao, Xiaoming Shen, Zenghui Yang, Seng Gao, Chuanqing Bao. Regulation of tumor cell function and sensitivity to 5-FU by circMFSD12 in colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(04): 294-302.
[10]	Yuegang Li, Xu Guan, Zhixun Zhao, Jichuan Quan, Meng Zhuang, Jianqiang Tang. Current international research status of NOSES surgery for colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(04): 321-328.
[11]	Chaofan Guo, Qibo Peng, Zhangqiang Zheng, Xiangyang Yu. Risk prediction and treatment research advances of low anterior resection syndrome [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(04): 335-340.
[12]	Ming Yang, Jinzhu Zhang, Xishan Wang. Interpretation of colorectal cancer prevalence trend data from 2013 to 2022 released by the National Tumor Registry [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(03): 177-181.
[13]	Shenghui Huang, Haoyang Ruan. Surgical strategies in laparoscopic surgery for patients with persistent descending mesocolon and colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(03): 182-188.
[14]	Jixin Zhang, Shuang Xie, Xuelian Wang, Zuyin Wu, Yanyang Liang, Chunxu Zhang. The clinical study of transnasal ileus tube combined with NOSES in the treatment of obstructive colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(03): 189-196.
[15]	Jinzhu Zhang, Shiwen Mei, Jinfeng Sun, Gang Hu, Wenlong Qiu, Guoli Li, Xin Wang, Xishan Wang, Jianqiang Tang. Prognostic factors analysis for long-term survival after radical surgery for primary rectal cancer with beyond mesorectal excision [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(03): 197-204.

Please choose a citation manager

Content to export